Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tenon Medical, Inc.TNON · Entity 2063 | Chief Commercial Officer | May 01, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tenon Medical, Inc.
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | IndirectBy SiVantage, Inc. | 243,584 |
Reported balance
After 2026-05-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 68,201 · Balance 243,584 F1: On May 1, 2026, Tenon Medical, Inc. ("Registrant") issued 276,228 shares of its common stock to SiVantage, Inc. ("SiVantage") pursuant to the Asset Purchase Agreement, dated August 1, 2025, by and between the Registrant and SiVantage, in connection with the achievement of a certain milestone set forth therein. The securities reported herein represent the reporting person's indirect pecuniary interest in the shares held by SiVantage based on the reporting person's 24.69% equity interest in SiVantage. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest. |
| Common stockSEC Table I · non-derivative | Direct | 239,281 |
Reported balance
Holding disclosure · report date 2026-05-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 239,281 |
Filing footnotes · ownership attribution and instrument terms
F1: On May 1, 2026, Tenon Medical, Inc. ("Registrant") issued 276,228 shares of its common stock to SiVantage, Inc. ("SiVantage") pursuant to the Asset Purchase Agreement, dated August 1, 2025, by and between the Registrant and SiVantage, in connection with the achievement of a certain milestone set forth therein. The securities reported herein represent the reporting person's indirect pecuniary interest in the shares held by SiVantage based on the reporting person's 24.69% equity interest in SiVantage. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 5, 2026 23:42 UTC | Tenon Medical, Inc. TNON · Entity 2063 | GrantCommon stock | 68,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-052436 · ownership.xml · nonDerivative · entry 1 Grawey Nathaniel A. · CIK 0002081212 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By SiVantage, Inc. Disclosed balance after: 243,584 F1 · ownership.nature: On May 1, 2026, Tenon Medical, Inc. ("Registrant") issued 276,228 shares of its common stock to SiVantage, Inc. ("SiVantage") pursuant to the Asset Purchase Agreement, dated August 1, 2025, by and between the Registrant and SiVantage, in connection with the achievement of a certain milestone set forth therein. The securities reported herein represent the reporting person's indirect pecuniary interest in the shares held by SiVantage based on the reporting person's 24.69% equity interest in SiVantage. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest. Read SEC document |
| November 14, 2025 Filed Nov 19, 2025 01:01 UTC | Tenon Medical, Inc. TNON · Entity 2063 | PurchaseCommon Stock Purchase Warrant · Derivative | 101,167 | Not disclosed Strike: $1.16 | Not disclosed |
DisclosureSEC source: 0001213900-25-112295 · ownership.xml · derivative · entry 3 Grawey Nathaniel A. · CIK 0002081212 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,167 Underlying: Common Stock · 101,167 shares Expires 2028-11-14 F1 · price: On November 10, 2025, the Issuer entered into a Securities Purchase Agreement for an at-the-market private investment in public equity transaction, in which the reporting person purchased 101,167 shares of common stock of the Issuer and warrants to purchase up to 101,167 shares of common stock of the Issuer. The purchase price for each share of common stock and accompanying warrant was $1.285. The offering closed on November 14, 2025. Read SEC document |
| November 14, 2025 Filed Nov 19, 2025 01:01 UTC | Tenon Medical, Inc. TNON · Entity 2063 | PurchaseCommon stock | 101,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-112295 · ownership.xml · nonDerivative · entry 1 Grawey Nathaniel A. · CIK 0002081212 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,281 F1 · price: On November 10, 2025, the Issuer entered into a Securities Purchase Agreement for an at-the-market private investment in public equity transaction, in which the reporting person purchased 101,167 shares of common stock of the Issuer and warrants to purchase up to 101,167 shares of common stock of the Issuer. The purchase price for each share of common stock and accompanying warrant was $1.285. The offering closed on November 14, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.